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background:  The important factor for efficacy and safety for patients with atrial fibrillation (AF) undergoing electrical cardioversion (ECV) 
is appropriate use of oral anticoagulant (OAC) therapy. Dabigatran (D) is a possible alternative before and after ECV versus warfarin (W).
Methods:  We have analysed the data collected before and after ECV in 1346 patients (pts) undergoing ECV. All pts had AF, 1056 
persistent and 290 long-acting, mean CHA2 DS2 VASc score was 3.6 ± 1.9, 895 had one or two ECV previously. 807 (59.9%) pts started 
the use of D, (505 pts 150 mg twice or 302 pts 110 mg twice) before ECV for at least 21 day, 539 (40.1%) started W,21 day start after INR 
was in range 2.0 - 3.0. 110 mg twice were used for pts ≥75 year, HASBLEED score ≥3 and kidney problems. Transesophageal echo (TEE) 
was encouraged before ECV in all pts with CHA2DS2VASc score ≥4, left atrial (LA) dilatation and AF duration ≥6 months. ECG and Echo-
kg data were analysed 30 and 90 days after ECV.
Methods: ECV was successful after first shock in 1239 (92 %) pts, total success ECV 1318 (97.9%) pts. LA thrombi were detected on TEE 
before ECV in 14 pts in D group and 28 pts in W group, so, pts continued OAC therapy for two month, and TEE had been performed again. 
7 pts in D (150 mg twice) and 4 pts in W group were free of thrombus and have been referred to ECV. Average time for treatment before 
ECV was significantly lower for D (25 days) vs W (48 days, p<0.01). Stroke and systemic embolism rates at 90 days were lower in both 
D groups (0.1%) vs W group (1.5%), but the event in both D groups was after discontinuation of the drug while 8 W events were detected 
under the time of OAC. There was no difference of events between TEE and non-TEE pts. D pts had significantly lower clinical relevant 
bleeding rate vs W (D 110 mg 0, D 150 mg 0.47% vs W 2.87%,p<0.04).
Conclusion: Dabigatran 150 mg and 110 mg twice is a safe, effective and reasonable alternative to warfarin for patients undergoing ECV 
despite high CHA2DS2VASc risk score, HASBLEED score and AF duration. The frequencies of stroke and embolic events were lower in 
dabigatran 150 mg and 110 mg versus warfarin with lower major bleeding within 30 and 90 days after ECV. Patients undergoing dabigatran 
therapy have shorter time before procedures.
